With Covid rev­enues falling, Pfiz­er lays out growth plans and pos­si­ble cost cuts

As the Pfiz­er be­he­moth con­tin­ues chug­ging along post-pan­dem­ic, the drug­mak­er is start­ing to clar­i­fy how its Covid-19 prof­its will turn in­to fu­ture growth.

For the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER